SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

2017327 citationsJournal Articlehybrid Open Access

Authors

Robert L. Avery · California Retina Consultants

Alessandro Castellarin · California Retina Consultants

Nathan Steinle · California Retina Consultants

Dilsher S. Dhoot · California Retina Consultants

Dante J. Pieramici · California Retina Consultants

Robert F. See · California Retina Consultants

Stephen Couvillion

Abstract

The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.

Topics & Keywords

Retinal Diseases and Treatments Complement system in diseases Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 37, Issue 10, pp. 1847-1858

DOI: 10.1097/iae.0000000000001493

Field-Weighted Citation Impact: 24.92